Omnicell (OMCL) Reports In-Line Q4 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Omnicell Reports Fiscal Year and Fourth Quarter 2021 Results
February 14, 2022 4:01 PM EST2021 Total Product Bookings of $1.217 billion
Full Year 2021 Revenues of $1.132 billion
Ended Year with 151 Long-Term, Sole-Source Agreements with the Top 300 U.S. Health Systems
Entered 2022 with Product Backlog of $1.254 billion
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- Omnicell, Inc. (NASDAQ: OMCL) (Omnicell, we, our, us, management, or the Company), a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies, today announced results for its fourth quarter and fiscal year ended December 31, 2021.
GAAP Results
Total... More
